| Adenocarcinoma studied in …STUDIED_INderived200 of 8,640show all (up to 200) |
|---|
| → studied in | NCT00423306Phase 2 · completed A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02345265Phase 2 · active not recruiting Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Fallopian Tube Endometrioid Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02446600Phase 3 · active not recruiting Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Fallopian Tube Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02502266Phase 2/Phase 3 · active not recruiting Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Fallopian Tube Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02613819Phase 2 · completed Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02883062Phase 2 · active not recruiting Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03348631Phase 2 · active not recruiting Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03598257Phase 2 · active not recruiting Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Breast Inflammatory Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03866382Phase 2 · recruiting Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Bladder Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03897543Phase 1/Phase 2 · completed ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04175912Phase 2 · active not recruiting Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04548752Phase 2 · active not recruiting Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04605913Phase 1/Phase 2 · active not recruiting Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04981509Phase 2 · recruiting Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Papillary Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05176223Phase 2 · completed 68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05256225Phase 3 · recruiting Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05273554Phase 1 · completed A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05564377Phase 2 · recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05877599Phase 1 · recruiting A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05891171Phase 1 · active not recruiting Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06058377Phase 3 · recruiting Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06203600Phase 2/Phase 3 · recruiting Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Esophageal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06505018NA · terminated Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06605664Phase 2 · recruiting Hyperpolarized 13C-MRI in Patients With Hepatocellular Carcinoma Undergoing Radiotherapy, Atezolizumab, and Bevacizumab · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06608927Phase 3 · active not recruiting Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06627712Phase 3 · recruiting SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06799065Phase 1/Phase 2 · recruiting First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07011719Phase 3 · recruiting Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07061977Phase 3 · recruiting Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Cervical Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07212491enrolling by invitation Minimally Invasive Molecular Approaches for the Detection of Barrett's Esophagus- High Grade Dysplasia and Esophageal Adenocarcinoma · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Esophageal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07504588Phase 2 · recruiting Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07574541Phase 2 · not yet recruiting Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07603375Phase 2 · recruiting Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Esophageal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07607769recruiting MONTEROSA - Italian Multicenter Observational Study to Evaluate Time to Clinical Hepatic Decompensation, Quality of Life, Effectiveness, and Safety of Tremelimumab Plus Durvalumab in Patients With Advanced or Unresectable Hepatocellular Carcinoma Who Have Received no Prior Systemic Treatment. · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07671417early Phase 1 · recruiting Imaging Study in Metastatic Clear Cell RCC. · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07705035Phase 1 · recruiting DBC-664 in Adult Patients With Solid Tumors · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Lung Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07770802Phase 1 · recruiting Clinical Study of HS-IT101 Injection in the Treatment of Advanced Renal Cancer · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07845617recruiting Hepatic Artery Infusion Pump Chemotherapy for Liver Metastases From Resected Pancreatic and Duodenal Adenocarcinoma · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07847398NA · not yet recruiting Emergence of Predictive Metabolomic Biomarkers of Response to Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer. · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07847671Phase 2 · not yet recruiting Fecal Microbiota Transplantation With QL1706 Plus Bevacizumab for Advanced HCC · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04071223Phase 2 · active not recruiting Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04644770Phase 1 · active not recruiting A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05007106Phase 2 · completed MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05112601Phase 2 · recruiting Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05482893Phase 1/Phase 2 · recruiting Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05540925completed Vascular Invasion Prediction Via a Multimodal Model Supports Re-staging of Early-stage Hepatocellular Carcinoma · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05956093NA · active not recruiting 68Ga-FAPI PET/CT in the Staging of High-Grade Epithelial Ovarian Cancers: A Pilot Study · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | High-Grade Serous Ovarian Cancer | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05965999recruiting Lucid Registry Study · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Esophageal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06120283Phase 1 · recruiting BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Hormone Receptor-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06388967recruiting Pancreatic Cancer Detection Consortium · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06586957Phase 1 · recruiting A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06726161Phase 1/Phase 2 · recruiting Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07078838Phase 2 · not yet recruiting Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07227012Phase 1/Phase 2 · recruiting Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body. · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07277413Phase 1 · recruiting A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | Esophageal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07305428NA · recruiting Downstaging Unresectable Hepatocellular Carcinoma to Resectable Disease With Combined Immunotherapy and Stereotactic Beamed Radiotherapy: a Pilot Study · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07391774Phase 3 · recruiting Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07392892Phase 2/Phase 3 · recruiting Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Esophageal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07594106Phase 1/Phase 2 · recruiting REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07621718Phase 3 · recruiting Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 ) · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07691762Phase 3 · not yet recruiting A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07698106Phase 1/Phase 2 · not yet recruiting Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07844057Phase 2 · not yet recruiting First-line Treatment in Locally Advanced or Metastastic Small Bowel Adenocarcinoma · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | Small Intestinal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07845266Phase 1 · completed Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GKL-006 Injection in Combination With TACE in Unresectable Hepatocellular Carcinoma · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02498613Phase 2 · active not recruiting A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02945579NA · recruiting Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03564340Phase 1/Phase 2 · recruiting Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Low-Grade Serous Ovarian Cancer | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03741426Phase 2 · recruiting WIRE - Novel Treatments in Renal Cell Cancer · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04123379Phase 2 · active not recruiting Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC) · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04626479Phase 1/Phase 2 · completed Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A) · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04626518Phase 1/Phase 2 · completed Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03) · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04858334Phase 2 · recruiting APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Pancreatic Acinar Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04981119recruiting Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05528133Phase 2 · recruiting Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05922930Phase 1/Phase 2 · active not recruiting Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06005493Phase 1/Phase 2 · recruiting Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06084234Phase 4 · recruiting National Liver Cancer Screening Trial · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06218914Phase 1 · recruiting Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06369610Phase 2 · active not recruiting Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Prostate Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06393374Phase 3 · recruiting Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06428409Phase 1/Phase 2 · recruiting A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06618664Phase 3 · recruiting A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma (KYLIN-02) · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06737913Phase 2 · recruiting HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06841354Phase 3 · recruiting A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06966700Phase 3 · recruiting A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06989437Phase 2/Phase 3 · recruiting A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07024680completed Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCC · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Papillary Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07066189NA · recruiting Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07124000recruiting DESTINY-PANTUMOUR04 · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07259317Phase 2 · recruiting Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07419880Phase 2 · not yet recruiting Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07489495Phase 3 · recruiting A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034) · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07562152Phase 3 · recruiting Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07670312Phase 1/Phase 2 · recruiting Evaluation of XYA02 in Patients With Advanced Solid Tumors · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07704970NA · recruiting QLESP Block for Pain Control in Robotic Partial Nephrectomy · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07748988Phase 1 · recruiting Casdatifan for the Treatment of Refractory Metastatic Clear Cell Renal Cell Carcinoma · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04145141completed National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04489771Phase 2 · completed A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013) · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04570956Phase 2 · terminated Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Breast Lobular Carcinoma In Situ | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05152147Phase 3 · active not recruiting A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Esophageal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05188118early Phase 1 · completed Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05575440terminated Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Thyroid Gland Follicular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06047379Phase 1/Phase 2 · recruiting Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06084780Phase 2 · not yet recruiting Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE) · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Pseudomyxoma Peritonei | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06179303Phase 2 · recruiting Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06882746Phase 1 · terminated A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07407920Phase 2 · recruiting Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Early Stage HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07408856Phase 1 · recruiting CAN1012 in Pre-Malignant DCIS and LCIS · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | Breast Lobular Carcinoma In Situ | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07820228completed Survival Analysis of Early Triple Negative Breast Cancer (TNBC) Women Treated With Dose Dense Sequential Adjuvant Chemotherapy · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07838415recruiting Multimodalomics-based Construction of Spatiotemporal Characteristics of Dynamic Liver Cancer Microenvironment to Characterize the Clinical Application of Immune Mechanisms in Liver Cancer · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07839767recruiting Treatment Selection by 3D Bioprinting Liver Model to Prevent Liver Cancer Recurrence · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07840001Phase 2 · not yet recruiting Neoadjuvant Belzutifan Plus Pembrolizumab in High-Risk, Locally Advanced Clear Cell Renal Cell Carcinoma · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07840092recruiting Biomarker Validation for Treatment Efficacy and Recurrence Prediction in Hepatocellular Carcinoma · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03981497recruiting Microwave Ablation for Treatment of Small Renal Tumors and Primary and Secondary Liver Neoplasms · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06253650Phase 2 · recruiting Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06915753Phase 1 · recruiting Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07025369Phase 2 · recruiting Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Prostate Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07085767Phase 3 · recruiting Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07214532NA · recruiting Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | Breast Ductal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07252232Phase 3 · recruiting Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07291076Phase 1/Phase 2 · recruiting A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206) · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07293351Phase 1/Phase 2 · recruiting A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208) · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07339176Phase 1/Phase 2 · recruiting Intratumoral N17350 in Advanced Solid Tumors · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07344220Phase 2 · enrolling by invitation Metastatic Non-Familial Adenocarcinoma Maintenance Therapy With DZ-002: Heptamine Carboxymethine Dye Conjugate · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07711847NA · recruiting Personalized Prone Immobilization for Accelerated Partial Breast Radiotherapy · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | Breast Ductal Carcinoma In Situ | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07835737Phase 1/Phase 2 · not yet recruiting Safety and Efficacy of Folic Acid Combined With Atezolizumab and Bevacizumab as First-Line Therapy for Unresectable Hepatocellular Carcinoma · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07836309not yet recruiting TACE in Combination With Tislelizumab and Lenvatinib for Advanced HCC (CHANCE2602) · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07836530Phase 3 · not yet recruiting Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Relapsed Hepatocellular Carcinoma · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07836712Phase 2 · not yet recruiting Multiple Adjunct Therapies to Improve Immunotherapy Treatment in Patients With Locally Advanced or Metastatic Melanoma or Advanced Hepatocellular Cancer · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04291651recruiting UCSF PANC Cyst Registry · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04810078Phase 3 · active not recruiting A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05276973Phase 1 · active not recruiting Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Fallopian Tube Endometrioid Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05422794Phase 1 · recruiting Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06066138Phase 1 · recruiting A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06109272Phase 2/Phase 3 · active not recruiting A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06128551Phase 1/Phase 2 · recruiting Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06445062Phase 1/Phase 2 · recruiting Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06858813Phase 1 · recruiting A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC) · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06863311Phase 2 · recruiting Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07409272Phase 3 · recruiting A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07488676Phase 1/Phase 2 · recruiting A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07528768Phase 2 · not yet recruiting HEADWATERS: Gemcitabine vs Paclitaxel in Metastatic Triple-Negative Breast Cancer in Women of African Ancestry. · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07596134NA · not yet recruiting Multimodal Thermal Therapy With Targeted and Immunotherapy for Untreated Unresectable HCC · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07619521Phase 1/Phase 2 · recruiting Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07769502Phase 2 · recruiting A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07801508Phase 1 · recruiting A Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid Tumors · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07833085NA · not yet recruiting CAIX-targeted PET/CT in Solid Tumors · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02620852NA · recruiting Women Informed to Screen Depending on Measures of Risk (Wisdom Study) · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Breast Carcinoma In Situ | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03455270Phase 1 · completed G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | Breast Ductal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03635892Phase 2 · active not recruiting A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma · condition mapped PROBABILISTIC · 8,640 trials mapped (2,941 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04084730Phase 2 · recruiting Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | Invasive Breast Carcinoma of No Special Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04295811NA · active not recruiting Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Esophageal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04543071Phase 2 · active not recruiting Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05550415Phase 2 · recruiting The Role of Simvastatin in The Epithelial-Mesenchymal Transition Process of Breast Cancer · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05920798Phase 1/Phase 2 · active not recruiting Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Fallopian Tube Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05983432Phase 1 · recruiting Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Prostate Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06005740Phase 1 · active not recruiting A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06040099Phase 2 · active not recruiting A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06176989Phase 2 · recruiting Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Sinonasal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06929845NA · recruiting Organoid Models of Hepatocellular Carcinoma · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07629960Phase 1/Phase 2 · recruiting A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07639138Phase 2 · recruiting Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07645651Phase 1 · recruiting Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07793695Phase 2 · recruiting Oral Zinc Supplementation Combined With Targeted Immunotherapy for Unresectable or Advanced Hepatocellular Carcinoma · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07829926Phase 2 · not yet recruiting Lenvatinib Plus Tislelizumab With or Without Gefitinib for Advanced Liver Cancer · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07831330Phase 2 · not yet recruiting Albumin-bound Paclitaxel (II) in Combination With Gemcitabine as First Line Therapy for Metastatic Pancreatic Cancer · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07832006Phase 2 · recruiting Irreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07832227Phase 2 · not yet recruiting Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | Ovarian Low Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02874885active not recruiting Circulating Tumor Cells in Patients With Locally Advanced Rectal Cancer · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Rectosigmoid Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03391869Phase 3 · active not recruiting Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Lung Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03776487Phase 2 · active not recruiting Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04053842Phase 2 · completed Multi-modality Imaging (PCa) Using Sodium MRI and PSMA PET in Men Pre-prostatectomy · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Prostate Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04090398Phase 2 · active not recruiting Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04638751suspended ARGONAUT: Stool and Blood Sample Bank for Cancer Patients · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04985565NA · active not recruiting Neoadjuvant Dietary Intervention in Intermediate Risk Prostate Cancer · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Prostate Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05048212Phase 2 · recruiting A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05327686Phase 2 · recruiting Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05863052active not recruiting Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06954116Phase 2 · recruiting Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07340541Phase 2 · recruiting Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07435038Phase 1/Phase 2 · recruiting Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07450859Phase 2 · recruiting A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07627191early Phase 1 · recruiting GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07650240Phase 2 · recruiting Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Prostate Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07688187Phase 1 · recruiting A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07705334Phase 1 · recruiting A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07827053Phase 2 · not yet recruiting Clinical Study of Radiotherapy Combined With Adebrelimab and NALIRIFOX for Conversion Therapy in Locally Advanced Pancreatic Cancer · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07827482completed Pretreatment 18F-FDG PET/CT Radiomics for Predicting Response to First-Line Targeted Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07827807Phase 2 · not yet recruiting PEARL Trial: Partial TACE Enhancing Anti-tumor Response With Lenvatinib in Unresectable HCC · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07828236Phase 1 · not yet recruiting PHASE 1 TRIAL OF Lm-LLO-TT AND GEMCITABINE IN UNRESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07828249Phase 1 · not yet recruiting Phase I Study Evaluating 161Tb-PSMA Therapy in Adult Patients With Metastatic Clear Cell Renal Cell Carcinoma · condition mapped CURATED_BROADER · 8,640 trials mapped (2,941 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07828652not yet recruiting Real-world Treatment Outcomes and Safety of Neoadjuvant Pembrolizumab-containing Therapy in Patients With Triple-negative Breast Cancer: Korean Nationwide Multicenter Study (Pembro-Real World) · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07829185Phase 1 · not yet recruiting Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02851784Phase 2/Phase 3 · recruiting Combination Therapy of Microwave Ablation and Cellular Immunotherapy for Hepatocellular Carcinoma · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04105270Phase 2 · recruiting RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | Lung Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04152499Phase 1/Phase 2 · active not recruiting Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01) · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04544111Phase 2 · active not recruiting PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | Thyroid Gland Follicular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04544748Phase 1 · completed A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05003752Phase 1/Phase 2 · active not recruiting Hypo-Combi Trial: Hypofractionated EBRT Plus HDR-BT Boost for Prostate Cancer · condition mapped ONTOLOGY_EXACT · 8,640 trials mapped (2,941 active) | — | — | Prostate Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05252585Phase 4 · active not recruiting A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML) · condition mapped ALIAS · 8,640 trials mapped (2,941 active) | — | — | Kidney Angiomyolipoma | 1 | Observed | clinicaltrials | graph → |